Literature DB >> 2295749

Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis.

A L Klein1, L K Hatle, D J Burstow, C P Taliercio, J B Seward, R A Kyle, K R Bailey, M A Gertz, A J Tajik.   

Abstract

To assess right ventricular diastolic function in cardiac amyloidosis, pulsed wave Doppler ultrasound measurements of right ventricular inflow velocities and superior vena cava and hepatic vein flow velocities with respiratory monitoring were performed in 41 patients with primary systemic amyloidosis and two-dimensional echocardiographic features of cardiac involvement. Right ventricular diastolic function was abnormal in 31 (76%) of these patients, the major abnormality being a short deceleration time (less than 150 ms) in 21 (68%), suggesting restriction. In contrast, 7 (23%) of the 31 patients had a decreased ratio of early (E) and late (A) diastolic peak flow velocities and a prolonged deceleration time (greater than 240 ms), suggesting abnormal relaxation. The patients were classified into two groups on the basis of right ventricular free wall thickness: group 1, less than 7 mm and group 2, greater than or equal to 7 mm. Compared with normal values, group 1 showed an increased peak late flow velocity (44 +/- 19 versus 39 +/- 6 cm/s; p less than 0.01) and a decreased E/A velocity ratio (1.1 +/- 0.4 versus 1.5 +/- 0.3; p less than 0.01). Group 2 showed a markedly shortened deceleration time (151 +/- 37 versus 225 +/- 28 ms; p less than 0.01), characteristic of restriction. In the overall group, superior vena cava peak flow velocity was decreased in systole and increased in diastole and flow reversals during inspiration were increased compared with normal values. Hepatic venous flow velocities were similar to those in the superior vena cava except for larger flow reversals in the hepatic vein. Thus, in cardiac amyloidosis, right ventricular diastolic function is abnormal. There is a spectrum of right ventricular filling abnormalities and the restrictive filling pattern is seen only in the advanced stages of the disease.

Entities:  

Mesh:

Year:  1990        PMID: 2295749     DOI: 10.1016/0735-1097(90)90183-p

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

1.  Role of echocardiography in assessing cardiac amyloidoses: a systematic review.

Authors:  Jun Koyama; Masatoshi Minamisawa; Yoshiki Sekijima; Koichiro Kuwahara; Tsutomu Katsuyama; Kazutoshi Maruyama
Journal:  J Echocardiogr       Date:  2019-02-11

Review 2.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

3.  Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

Authors:  Sohsuke Meshitsuka; Sumito Shingaki; Masatoshi Hotta; Miku Goto; Makoto Kobayashi; Yuuichi Ukawa; Yuko M Sagesaka; Yasuyo Wada; Masanori Nojima; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2016-11-04       Impact factor: 2.490

4.  Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al).

Authors:  Diego Bellavia; Roshini S Abraham; Patricia A Pellikka; Angela Dispenzieri; John C Burnett; Ghormallah B Al-Zahrani; Tammy D Green; Michelle K Manske; Morie A Gertz; Fletcher A Miller; Theodore P Abraham
Journal:  J Am Soc Echocardiogr       Date:  2011-02-18       Impact factor: 5.251

5.  Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension.

Authors:  A Giunta; E Tirri; S Maione; S Cangianiello; A Mele; A De Luca; G Valentini
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

6.  Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis.

Authors:  Derliz Mereles; Sebastian J Buss; Stefan E Hardt; Werner Hunstein; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2010-03-10       Impact factor: 5.460

Review 7.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Perry Elliott; Raymond Comenzo; Marc Semigran; Claudio Rapezzi
Journal:  Circulation       Date:  2017-04-04       Impact factor: 29.690

Review 8.  Echocardiographic assessment of cardiac amyloidosis.

Authors:  Tanushree Agrawal; Sherif F Nagueh
Journal:  Heart Fail Rev       Date:  2021-08-30       Impact factor: 4.654

9.  Abnormal right heart filling after cardiac surgery: time course and mechanisms.

Authors:  B Wranne; F J Pinto; E Hammarström; F G St Goar; J Puryear; R L Popp
Journal:  Br Heart J       Date:  1991-12

10.  Estimation of Right Atrial Pressure from the Inspiratory Collapse of the Inferior Vena cava in Pediatric Patients.

Authors:  Hamid Amoozgar; Khobiar Zare; Gholamhossein Ajami; Mohammad Borzoee; Saeed Abtahi
Journal:  Iran J Pediatr       Date:  2010-06       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.